Testing efimosfermin against placebo in adults with cirrhosis from MASH
Tests efimosfermin, compared with placebo, in adults with cirrhosis caused by MASH.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Key facts
- Where
- Arcadia, Arlington, Arroyo Grande, Austin, Bellaire, Cape Coral, Dallas, East Syracuse, Folsom, Fort Myers, Hialeah, Homestead, Houston, Humble, Kissimmee, Lakeland, Little Rock, Manassas, Miami, Morehead City, New York, Ocala, San Antonio, Springboro, St Louis, University Park, Van Nuys, Waco, West Jordan, and Westlake, United StatesSee the 30 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07704892, who can take part
Where in United States
- ArcadiaArcadia, United StatesTaking people
- ArlingtonArlington, United StatesTaking people
- Arroyo GrandeArroyo Grande, United StatesTaking people
- AustinAustin, United StatesTaking people
- BellaireBellaire, United StatesTaking people
- Cape CoralCape Coral, United StatesTaking people
- DallasDallas, United StatesTaking people
- East SyracuseEast Syracuse, United StatesTaking people
- FolsomFolsom, United StatesTaking people
- Fort MyersFort Myers, United StatesTaking people
- HialeahHialeah, United StatesTaking people
- HomesteadHomestead, United StatesTaking people
- HoustonHouston, United StatesTaking people
- HumbleHumble, United StatesTaking people
- KissimmeeKissimmee, United StatesTaking people
- LakelandLakeland, United StatesTaking people
- Little RockLittle Rock, United StatesTaking people
- ManassasManassas, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Morehead CityMorehead City, United StatesTaking people
- New YorkNew York, United StatesTaking people
- OcalaOcala, United StatesTaking people
- San AntonioSan Antonio, United StatesTaking people
- SpringboroSpringboro, United StatesTaking people
- St LouisSt Louis, United StatesTaking people
- University ParkUniversity Park, United StatesTaking people
- Van NuysVan Nuys, United StatesTaking people
- WacoWaco, United StatesTaking people
- West JordanWest Jordan, United StatesTaking people
- WestlakeWestlake, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GlaxoSmithKline
- Trial code
- NCT07704892
- Record updated
- 5 November 2026
- Original description
This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusion criteria will have the option to enroll in Part B (open label) of the study.Read full original descriptionShow less
A Phase 3, Two-part, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis (Stage F4 Fibrosis) Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-2)
This is a multi-center, randomized, two-part (Part A and Part B) study investigating the safety and efficacy of efimosfermin alfa in adult participants with compensated cirrhosis due to MASH. Participants who complete the treatment during Part A of the study and meet the inclusion criteria will have the option to enroll in Part B (open label) of the study.
Inclusion: Participants aged between 18 and 75 years at enrolment; Participants with history or presence of at least two components of metabolic syndrome; Liver biopsy consistent with cirrhosis (fibrosis stage 4).
Exclusion: History or evidence of chronic pancreatic disease; pancreatic injury or acute pancreatitis within 6 months before Screening; A recent history or planned surgical procedures or medications intended to produce significant weight loss; Participants with other chronic liver diseases; Participants with evidence or history of decompensated liver disease or hepatocellular carcinoma; Participants with history of Type 1 diabetes mellitus; or major Type 2 diabetes mellitus complications; Current or history of excessive alcohol intake; Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >= 5 times upper limit normal (ULN).